

Jillian R Gunther

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/348278/publications.pdf>

Version: 2024-02-01

86
papers

1,396
citations

471061

17
h-index

360668

35
g-index

86
all docs

86
docs citations

86
times ranked

2364
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical evidence of variable proton biological effectiveness in pediatric patients treated for ependymoma. <i>Radiotherapy and Oncology</i> , 2016, 121, 395-401.	0.3	210
2	Bridging therapy prior to axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma. <i>Blood Advances</i> , 2020, 4, 2871-2883.	2.5	134
3	Imaging Changes in Pediatric Intracranial Ependymoma Patients Treated With Proton Beam Radiation Therapy Compared to Intensity Modulated Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 93, 54-63.	0.4	108
4	H19 Noncoding RNA, an Independent Prognostic Factor, Regulates Essential Rb-E2F and CDK8- β -Catenin Signaling in Colorectal Cancer. <i>EBioMedicine</i> , 2016, 13, 113-124.	2.7	106
5	Reclassifying patients with early-stage Hodgkin lymphoma based on functional radiographic markers at presentation. <i>Blood</i> , 2018, 131, 84-94.	0.6	78
6	A PET Radiomics Model to Predict Refractory Mediastinal Hodgkin Lymphoma. <i>Scientific Reports</i> , 2019, 9, 1322.	1.6	62
7	Simulation as More Than a Treatment-Planning Tool: A Systematic Review of the Literature on Radiation Oncology Simulation-Based Medical Education. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, 257-283.	0.4	41
8	Pre-treatment neutrophil/lymphocyte ratio and platelet/lymphocyte ratio are prognostic of progression in early stage classical Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2018, 180, 545-549.	1.2	38
9	Proton beam therapy outcomes for localized unresectable hepatocellular carcinoma. <i>Radiotherapy and Oncology</i> , 2019, 133, 54-61.	0.3	37
10	Primary cutaneous B-cell lymphoma (non-leg type) has excellent outcomes even after very low dose radiation as single-modality therapy. <i>Leukemia and Lymphoma</i> , 2016, 57, 34-38.	0.6	34
11	Multi-institutional Randomized Trial Testing the Utility of an Interactive Three-dimensional Contouring Atlas Among Radiation Oncology Residents. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 98, 547-554.	0.4	31
12	Outcomes After Reduced-Dose Intensity Modulated Radiation Therapy for Gastric Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 104, 447-455.	0.4	31
13	Coronary Artery Dose-Volume Parameters Predict Risk of Calcification After Radiation Therapy. <i>Journal of Cardiovascular Imaging</i> , 2019, 27, 268.	0.2	30
14	Effectiveness of definitive radiotherapy for squamous cell carcinoma of the vulva with gross inguinal lymphadenopathy. <i>Gynecologic Oncology</i> , 2018, 148, 474-479.	0.6	24
15	Predictors of Hypothyroidism in Hodgkin Lymphoma Survivors After Intensity Modulated Versus 3-Dimensional Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 101, 530-540.	0.4	23
16	Positron emission tomography-computed tomography predictors of progression after DA-R-EPOCH for PMBCL. <i>Blood Advances</i> , 2018, 2, 1334-1343.	2.5	23
17	Craniospinal irradiation prior to stem cell transplant for hematologic malignancies with CNS involvement: Effectiveness and toxicity after photon or proton treatment. <i>Practical Radiation Oncology</i> , 2017, 7, e401-e408.	1.1	21
18	Radiation and CAR T-cell Therapy in Lymphoma: Future Frontiers and Potential Opportunities for Synergy. <i>Frontiers in Oncology</i> , 2021, 11, 648655.	1.3	19

#	ARTICLE	IF	CITATIONS
19	Preoperative radiation dose escalation for rectal cancer using a concomitant boost strategy improves tumor downstaging without increasing toxicity: A matched-pair analysis. <i>Advances in Radiation Oncology</i> , 2017, 2, 455-464.	0.6	18
20	An international multicenter retrospective analysis of patients with extranodal marginal zone lymphoma and histologically confirmed central nervous system and dural involvement. <i>Cancer Medicine</i> , 2020, 9, 663-670.	1.3	17
21	Radiation Therapy as an Effective Salvage Strategy for Secondary CNS Lymphoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 100, 1146-1154.	0.4	15
22	Radiation therapy for salivary gland MALT lymphoma: ultra-low dose treatment achieves encouraging early outcomes and spares salivary function. <i>Leukemia and Lymphoma</i> , 2020, 61, 171-175.	0.6	14
23	Introductory Radiation Oncology Curriculum: Report of a National Needs Assessment and Multi-institutional Pilot Implementation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 101, 1029-1038.	0.4	13
24	Genomic and Transcriptomic Characterisation of Response to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer. <i>Cancers</i> , 2020, 12, 1808.	1.7	13
25	The Impact of an Introductory Radiation Oncology Curriculum (IROC) for Radiation Oncology Trainees Across the United States and Canada. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 107, 408-416.	0.4	13
26	Primary breast diffuse large B-cell lymphoma: treatment strategies and patterns of failure. <i>Leukemia and Lymphoma</i> , 2018, 59, 2896-2903.	0.6	12
27	Favorable outcomes with de-escalated radiation therapy for limited-stage nodular lymphocyte-predominant Hodgkin lymphoma. <i>Blood Advances</i> , 2019, 3, 1356-1367.	2.5	12
28	Emerging Treatment Strategies for Primary Breast Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 244-250.	0.2	11
29	Effect of Deep Inspiration Breath Hold on Normal Tissue Sparing With Intensity Modulated Radiation Therapy Versus Proton Therapy for Mediastinal Lymphoma. <i>Advances in Radiation Oncology</i> , 2020, 5, 1255-1266.	0.6	11
30	The Radiation Oncology Education Collaborative Study Group 2020 Spring Symposium: Is Virtual the New Reality?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 110, 315-321.	0.4	11
31	A Prostate Fossa Contouring Instructional Module: Implementation and Evaluation. <i>Journal of the American College of Radiology</i> , 2016, 13, 835-841.e1.	0.9	10
32	Chemotherapy Response Assessment by FDG-PET-CT in Early-stage Classical Hodgkin Lymphoma: Moving Beyond the Five-Point Deauville Score. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 97, 333-338.	0.4	10
33	Decreased heart dose with deep inspiration breath hold for the treatment of gastric lymphoma with IMRT. <i>Clinical and Translational Radiation Oncology</i> , 2020, 24, 79-82.	0.9	10
34	New paradigm for radiation in multiple myeloma: lower yet effective dose to avoid radiation toxicity. <i>Haematologica</i> , 2020, 105, e355-e357.	1.7	10
35	Analyzing the Role of Research in the Radiation Oncology Match. <i>Advances in Radiation Oncology</i> , 2022, 7, 100891.	0.6	10
36	Treatment of Early-Stage Unfavorable Hodgkin Lymphoma: Efficacy and Toxicity of 4 Versus 6 Cycles of ABVD Chemotherapy With Radiation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, 110-118.	0.4	9

#	ARTICLE	IF	CITATIONS
37	Early-stage Hodgkin lymphoma outcomes after combined modality therapy according to the post-chemotherapy 5-point score: can residual pet-positive disease be cured with radiotherapy alone?. <i>British Journal of Haematology</i> , 2017, 179, 488-496.	1.2	9
38	Response-adapted radiation therapy for newly diagnosed primary diffuse large B-cell lymphoma of the CNS treated with methotrexate-based systemic therapy. <i>Advances in Radiation Oncology</i> , 2018, 3, 639-646.	0.6	9
39	Outcome of relapsed and refractory nodular lymphocyte-predominant Hodgkin lymphoma: a North American analysis. <i>British Journal of Haematology</i> , 2021, 192, 560-567.	1.2	9
40	Assessment of Radiation Doses Delivered to Organs at Risk Among Patients With Early-Stage Favorable Hodgkin Lymphoma Treated With Contemporary Radiation Therapy. <i>JAMA Network Open</i> , 2020, 3, e2013935.	2.8	8
41	Phase I Trial of Consolidative Radiotherapy with Concurrent Bevacizumab, Erlotinib and Capecitabine for Unresectable Pancreatic Cancer. <i>PLoS ONE</i> , 2016, 11, e0156910.	1.1	8
42	Postoperative Radiotherapy for Multiple Myeloma of Long Bones: Should the Entire Rod Be Treated?. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e465-e469.	0.2	7
43	Frontline antibiotic therapy for early-stage <i>Helicobacter pylori</i> -negative gastric MALT lymphoma. <i>American Journal of Hematology</i> , 2019, 94, E150-E153.	2.0	7
44	Hitting a Moving Target: Successful Management of Diffuse Large B-cell Lymphoma Involving the Mesentery With Volumetric Image-guided Intensity Modulated Radiation Therapy. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e51-e61.	0.2	7
45	Does Bleomycin Lung Toxicity Increase the Risk of Radiation Pneumonitis in Hodgkin Lymphoma?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, 951-958.	0.4	6
46	Identification of Blood-Based Biomarkers for the Prediction of the Response to Neoadjuvant Chemoradiation in Rectal Cancer. <i>Cancers</i> , 2021, 13, 3642.	1.7	6
47	Radiation Therapy Can be an Effective Bridging Strategy Prior to Axicabtagene Ciloleucel Therapy for Relapsed/Refractory Large B-Cell Lymphoma. <i>Blood</i> , 2019, 134, 1609-1609.	0.6	6
48	Partial omission of bleomycin for early-stage Hodgkin lymphoma patients treated with combined modality therapy: Does incomplete ABVD lead to inferior outcomes?. <i>EJHaem</i> , 2020, 1, 272-276.	0.4	5
49	Outcomes After Chemotherapy Followed by Radiation for Stage IIB Hodgkin Lymphoma With Bulky Disease. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 664-670.e2.	0.2	4
50	The impact of cell-of-origin, MYC/Bcl-2 dual expression and <i>MYC</i> rearrangement on disease relapse among early stage diffuse large B-cell lymphoma patients treated with combined modality therapy. <i>Leukemia and Lymphoma</i> , 2021, 62, 1361-1369.	0.6	4
51	Early Stage Extranodal Follicular Lymphoma: Characteristics, Management, and Outcomes. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 381-389.	0.2	3
52	In Regard to Marcrom et al. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 104, 220-221.	0.4	3
53	Daily computed tomography image guidance: Dosimetric advantages outweigh low-dose radiation exposure for treatment of mediastinal lymphoma. <i>Radiotherapy and Oncology</i> , 2020, 152, 14-18.	0.3	3
54	In Regard to Ahmed et al. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 94, 1221-1222.	0.4	2

#	ARTICLE	IF	CITATIONS
55	Omitting cardiophrenic lymph nodes in the treatment of patients with Hodgkin lymphoma via modified involved-site radiation therapy. <i>Leukemia and Lymphoma</i> , 2018, 59, 2650-2659.	0.6	2
56	Coincident primary breast lymphoma and gastrointestinal stromal tumor: case series and molecular mechanisms. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 8937-8942.	1.0	2
57	Limited stage grade 3 follicular lymphoma patients can experience favorable outcomes with combined modality therapy. <i>Leukemia and Lymphoma</i> , 2019, 60, 2432-2440.	0.6	2
58	Imaging Surveillance of Limited-stage Classic Hodgkin Lymphoma Patients After PET-CT-documented First Remission. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 533-541.	0.2	2
59	Renal lymphomatous infiltration by mantle cell lymphoma: Treatment with chemoradiation and initiation of angiotensin converting enzyme (ACE) inhibitor for renal protection. <i>Journal of Onco-Nephrology</i> , 0, , 239936932110398.	0.3	2
60	Assessment of Lymphoma and Other Hematologic Malignancies Training Needs Among Radiation Oncology Residents: a Brief Report. <i>Journal of Cancer Education</i> , 2023, 38, 201-205.	0.6	2
61	Treatment and Outcome of Patients with Follicular Lymphoma Relapsed or Progressed after Frontline Lenalidomide and Rituximab. <i>Blood</i> , 2020, 136, 31-32.	0.6	2
62	Radiotherapy in Patients with Mycosis Fungoides and Central Nervous System Involvement. <i>Case Reports in Oncology</i> , 2018, 11, 721-728.	0.3	1
63	Additional therapy improves outcomes in completely resected, limited-stage follicular lymphoma. <i>Leukemia and Lymphoma</i> , 2019, 60, 3258-3265.	0.6	1
64	ILROG Lymphoma Mini-Atlas Part II, Hodgkin Lymphoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, 977-978.	0.4	1
65	A Not So Perfect Score: Factors Associated with the Rate of Straight Line Scoring in Oncology Training Programs. <i>Journal of Cancer Education</i> , 2020, , 1.	0.6	1
66	Radiation Oncology Education Collaborative Study Group Annual Spring Symposium: Initial Impact and Feedback. <i>Journal of Cancer Education</i> , 2022, 37, 1504-1509.	0.6	1
67	Association of Vitamin D Deficiency with Inferior Treatment Outcomes in Patients with Newly Diagnosed Classic Hodgkin Lymphoma: MD Anderson Cancer Center Experience. <i>Blood</i> , 2020, 136, 27-28.	0.6	1
68	Implementation and Assessment of an Informal Virtual Elective for Medical Student Radiation Oncology Exploration During the COVID19 Pandemic: a Brief Report. <i>Journal of Cancer Education</i> , 2023, 38, 344-348.	0.6	1
69	Rainbow IMRT and Volumetric Imaging for Anterior Mesenteric Targets. <i>Practical Radiation Oncology</i> , 2019, 9, 147-152.	1.1	0
70	Post-ABVD biopsy results, and not post-ABVD FDG-PET results, predict outcome in early-stage Hodgkin lymphoma: response to Adams and Kwee. <i>British Journal of Haematology</i> , 2019, 184, 292-293.	1.2	0
71	Involved-Site Radiation Therapy if Minimal Toxicity. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 107, 20-21.	0.4	0
72	Radiation Pneumonitis Risk after Bleomycin Toxicity in Hodgkin Lymphoma Patients. <i>Blood</i> , 2015, 126, 1511-1511.	0.6	0

#	ARTICLE	IF	CITATIONS
73	Maintenance Rituximab in Nodular Lymphocyte Predominant Hodgkin Lymphoma (NLPHL) in the First Line Setting or at Relapse. Blood, 2019, 134, 5291-5291.	0.6	0
74	High-Dose Chemotherapy (HDC) with Autologous Stem-Cell Transplant (ASCT) with Consolidative Radiation Therapy (RT) for Relapsed or Refractory (R/R) Primary Mediastinal B-Cell Lymphoma (PMBCL): 20-Year Experience at MD Anderson Cancer Center (MDACC). Blood, 2020, 136, 32-33.	0.6	0
75	The evolving evidence for the efficacy and safety of charged particle therapy for hepatocellular carcinoma-a commentary. Annals of Translational Medicine, 2015, 3, 364.	0.7	0
76	Long Term Outcome Patterns and Risk Factors for Early Mortality and Disease Progression in ALK-Positive Anaplastic Large Cell Lymphoma. Blood, 2021, 138, 2463-2463.	0.6	0
77	Outcomes of Patients with Extranodal Natural Killer/T-Cell Lymphoma: Single Institution Series. Blood, 2021, 138, 4536-4536.	0.6	0
78	Phase II Trial of Response Adapted Ultra Low Dose (ULD) Orbital Radiation Therapy for Indolent B Cell Lymphoma. Blood, 2021, 138, 3526-3526.	0.6	0
79	Outcome of Patients with T- Cell Histiocyte Rich B Cell Lymphoma: Single Institution Series. Blood, 2021, 138, 1448-1448.	0.6	0
80	Radiomic Phenotypes of High and Low Lesion SUV Components for the Prediction of Refractory Disease in Hodgkin's Lymphoma Patients Treated with ABVD Based Therapy. Blood, 2021, 138, 3996-3996.	0.6	0
81	Association of Epstein-Barr Virus with Advanced Stage and Survival Outcomes in Classic Hodgkin's Lymphoma. Blood, 2020, 136, 37-38.	0.6	0
82	Factors Associated with the Improvement of Outcomes of High-Risk Relapsed Hodgkin Lymphoma (HL) Patients Receiving High-Dose Chemotherapy (HDC) and Autologous Stem-Cell Transplantation (ASCT): The MD Anderson Cancer Center Experience. Blood, 2020, 136, 17-18.	0.6	0
83	Association of Smoking with Advanced Stage and Survival Outcomes in Classic Hodgkin's Lymphoma. Blood, 2020, 136, 34-35.	0.6	0
84	Brentuximab Vedotin with Chemotherapy in Frontline Treatment of Classic Hodgkin Lymphoma Nodular Sclerosis Syncytial Variant. Blood, 2020, 136, 28-29.	0.6	0
85	Retrospective Review of Prognostic and Predictors Markers in Newly Diagnosed Angioimmunoblastic T Cell Lymphoma at UT MD Anderson Cancer Center. Blood, 2020, 136, 27-28.	0.6	0
86	Real Life Treatment Alterations of Frontline Therapies in Classic Hodgkin's Lymphoma. Blood, 2020, 136, 23-24.	0.6	0